SGLT-2 inhibitors are associated with lower rates of mortality following myocardial infarction in patients with type 2 diabetes - A SWEDEHEART observational study

27 August 2023 (09:06 - 09:24)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Hans Christian Rosen

Lund (Sweden)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on pharmacotherapy for acute coronary syndromes

Professor G. Montalescot (Paris, FR)

Presentation thumbnail

Incidence and pattern of repeat coronary revascularizations in patients with acute coronary syndromes treated with ticagrelor or prasugrel

Doctor A. Aytekin (Munich, DE)

Abstract Slides Video

Presentation thumbnail

Current concepts of treatment for left ventricular thrombus: A sys-tematic meta-analysis comparing direct oral anticoagulants versus vitamin K-antagonists

Mr T. Seiler (Bern, CH)

Abstract Slides Video

Presentation thumbnail

Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry

Mr A. Haakansson (Lund, SE)

Abstract Slides Video

Access the full session

Session thumbnail

Pharmacotherapy in acute coronary syndromes

The Event

Event poster

ESC Congress 2023

27 August 2023 09:06 CET

You may be interested in

Congress Session

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Congress Presentation

Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes

Congress Presentation

Impact of sglt2 inhibitors on cardiovascular outcomes in patients with acute myocardial infarction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources